LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Search

Dr Reddy's Laboratories Ltd-ADR

Geschlossen

BrancheGesundheitswesen

13.61 0.81

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.49

Max

13.81

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.4B

12B

Verkäufe

-783M

87B

KGV

Branchendurchschnitt

18.25

51.415

Dividendenrendite

0.7

Gewinnspanne

13.633

Angestellte

27,811

EBITDA

-4.7B

20B

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.70%

2.34%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

209M

11B

Vorheriger Eröffnungskurs

12.8

Vorheriger Schlusskurs

13.61

Nachrichtenstimmung

By Acuity

50%

50%

155 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Okt. 2025, 14:47 UTC

Wichtige Markttreiber

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

12. Mai 2026, 12:16 UTC

Ergebnisse

Dr. Reddy's Co-Chairman: Branded Businesses, Currency Tailwinds Partially Mitigated Impact >500124.BY

12. Mai 2026, 12:16 UTC

Ergebnisse

Dr. Reddy's Co-Chairman: FY Performance Reflects Impact of Lower Lenalidomide Sales, Several One-Offs >500124.BY

12. Mai 2026, 12:08 UTC

Ergebnisse

Dr. Reddy's Laboratories Board Recommends Final Dividend of INR8/Shr >500124.BY

12. Mai 2026, 12:06 UTC

Ergebnisse

Dr. Reddy's Laboratories 4Q EPS INR2.64 >500124.BY

12. Mai 2026, 12:02 UTC

Ergebnisse

Dr. Reddy's Laboratories 4Q Net INR2.2B Vs. Net INR15.9B >500124.BY

12. Mai 2026, 12:01 UTC

Ergebnisse

Dr. Reddy's Laboratories 4Q Rev INR75.16B Vs. INR85.06B >500124.BY

23. Juli 2025, 17:49 UTC

Ergebnisse

Dr. Reddy's Labs 1Q Global Generics Revenue $75.62B >RDY

23. Juli 2025, 17:48 UTC

Ergebnisse

Dr. Reddy's Labs 1Q EPS $17.02 >RDY

23. Juli 2025, 17:48 UTC

Ergebnisse

Dr Reddy's Labs 1Q Rev $85.45B >RDY

Peer-Vergleich

Kursveränderung

Dr Reddy's Laboratories Ltd-ADR Prognose

Rating-Konsens

By TipRanks

Sell

1 ratings

0

Buy

0

Halten

1

Sell

Technischer Score

By Trading Central

N/A / 13.84Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

155 / 345 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
help-icon Live chat